Contact Us

Have a question, need assistance, or want to book an appointment? Our team is here to help. Reach out anytime and we’ll get back to you as soon as possible.

FAQs

Frequently Asked Questions

What is Bio-Hybrid Therapeutics developing?

Bio-Hybrid Therapeutics is developing biologic medications focused on allergic diseases, including Atopic Dermatitis, Rhinitis, IBS, and anaphylaxis-related allergic reactions.

What is BHT002D™?

BHT002D™ is Bio-Hybrid Therapeutics’ lead patent-pending biologic candidate for Atopic Dermatitis. It is intended to prevent allergic reactive symptoms caused by specific protein allergens.

Is BHT002D™ approved by the FDA?

BHT002D™ is set to begin clinical trials in Summer 2027.

Who is Bio-Hybrid Therapeutics designed to serve?

The primary audience includes healthcare providers, allergists, and immunologists. Secondary audiences include patients with severe or chronic allergic conditions, and tertiary audiences include biotech investors and research institutions.

What makes Bio-Hybrid Therapeutics different?

Bio-Hybrid Therapeutics is focused on prevention, precision, simplicity, and biologic innovation, with a brand voice that balances scientific rigor and human empathy.

The Future of Allergy Relief Starts at the Source

Bio-Hybrid Therapeutics is advancing a focused biologic pipeline designed to improve quality of life for people living with allergic diseases. Our immune globulin therapies offers a targeted approach to allergy prevention — built for today’s clinical needs. Connect with our team to learn more about our science, pipeline, and partnership opportunities.

Bio-Hybrid Therapeutics is advancing a focused biologic pipeline designed to improve quality of life for people living with allergic diseases. Our immune globulin therapies offers a targeted approach to allergy prevention — built for today’s clinical needs. Connect with our team to learn more about our science, pipeline, and partnership opportunities.

Contact Bio-Hybrid Therapeutics